<p>藥明康德集團股票（NASDAQ:PHAR - 獲取免費報告）週三交易量不尋常地高。大約有 10,737 股在午間交易時交易，較前一交易日的 4,336 股增加了 148%。該股最新交易價為$8.18，之前收盤價為$7.82。</p>
<p>獲取 <strong>藥明康德集團</strong> 警報：</p>
<h2>華爾街分析師觀點</h2>
<p>另外，HC Wainwright 重申了對藥明康德集團股票的 “買入” 評級，並在 8 月 1 日星期四的研究報告中發佈了 37.00 美元的目標價。</p>
<p><strong>查看我們對藥明康德集團的最新研究報告</strong></p>
<h2>藥明康德集團股價上漲 4.6%</h2>
<p>該公司市值為 5.5087 億美元，市盈率為-48.88，β係數為 0.15。公司的流動比率為 3.39，速動比率為 2.65，負債權益比為 0.40。公司的 50 天簡單移動平均線為$8.14，200 天簡單移動平均線為$9.60。</p>
<p>藥明康德集團（NASDAQ:PHAR - 獲取免費報告）上次發佈財報是在 8 月 1 日星期四。公司當季每股收益為（$0.01）。藥明康德集團的淨資產收益率為-5.69%，淨利潤率為-4.65%。該季度公司的營收為 7409 萬美元，而分析師預期為 7195 萬美元。去年同期，該公司每股收益為$0.02。研究分析師預測，藥明康德集團今年財年每股盈利將為-0.03 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一家對沖基金最近增加了對藥明康德集團股票的持股。Silverberg Bernstein Capital Management LLC 根據最新提交給證券交易委員會的 13F 文件顯示，該基金在第二季度增持了藥明康德集團（NASDAQ:PHAR - 免費報告）的股份，增幅為 32.3%。該機構投資者在該時期內新增了 5725 股，持有公司股票 23435 股。Silverberg Bernstein Capital Management LLC 持有的藥明康德集團股份價值 196,000 美元。目前有 0.03% 的股份由機構投資者和對沖基金持有。</p>
<h2>藥明康德集團公司簡介（獲取免費報告）</h2>
<p>藥明康德集團 N.V.是一家生物製藥公司，致力於開發和銷售用於治療罕見疾病的蛋白替代療法和精準藥物，在美國、歐洲和國際市場銷售。該公司提供 RUCONEST，一種重組 C1 酯酶抑制劑，用於治療成年和青少年急性家族性性水腫（HAE）患者的急性發作；以及 Joenja（leniolisib），一種口服小分子 PI3Kδ抑制劑，用於治療活化磷脂酰肌醇 3-激酶δ綜合徵。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>3 家健康押息股票值得購買</li>
<li>Target 擊中目標：第二季度盈利超出預期</li>
<li>如何開始投資房地產</li>
<li>特斯拉的反彈剛剛開始？為什麼你應該考慮購買</li>
<li>投資者必須瞭解的場外交易股票</li>
<li>Stanley Druckenmiller 的最新賭注：MELI—你應該跟隨嗎？</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 精英們的陰謀：控制特朗普和你的金錢！（來自 Golden Crest）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0"/></p>
<h2>您現在是否應該投資$1,000 購買藥明康德集團股票？</h2>
<p>在考慮購買藥明康德集團股票之前，您可能需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而藥明康德集團不在名單上。</p>
<p>儘管藥明康德集團目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PHAR

<p>Pharming Group（納斯達克股票代碼：PHAR）經歷了異常高的交易量，約有 10,737 股交易，較上一交易日增長了 148%。該股最新交易價為$0.18，低於上一交易日的$0.82。HC Wainwright 的分析師維持了對該股的 “買入” 評級，並設定目標價為$1.00。Pharming 上季度報告的營收為 509 萬美元，低於預期。該公司的市值為 2.8787 億美元，以在罕見疾病領域的生物製藥開發而聞名。機構投資者持有該股的 0.03%，最近注意到了持股的重大變化</p>

<p>Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 10,737 shares were traded during mid-day trading, an increase of 148% from the previous session's volume of 4,336 shares.The stock last traded at $8.18 and had previously closed at $7.82.</p>
<div class="lb-trans"><p>藥明康德集團股票（NASDAQ:PHAR - 獲取免費報告）週三交易量不尋常地高。大約有 10,737 股在午間交易時交易，較前一交易日的 4,336 股增加了 148%。該股最新交易價為$8.18，之前收盤價為$7.82。</p>
</div><p>Get <strong>Pharming Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>藥明康德集團</strong> 警報：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.</p>
<div class="lb-trans"><p>另外，HC Wainwright 重申了對藥明康德集團股票的 “買入” 評級，並在 8 月 1 日星期四的研究報告中發佈了 37.00 美元的目標價。</p>
</div><p><strong>Check Out Our Latest Research Report on Pharming Group</strong></p>
<div class="lb-trans"><p><strong>查看我們對藥明康德集團的最新研究報告</strong></p>
</div><h2>Pharming Group Stock Up 4.6 %</h2>
<div class="lb-trans"><h2>藥明康德集團股價上漲 4.6%</h2>
</div><p>The firm has a market cap of $550.87 million, a P/E ratio of -48.88 and a beta of 0.15. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The company's 50 day simple moving average is $8.14 and its 200-day simple moving average is $9.60.</p>
<div class="lb-trans"><p>該公司市值為 5.5087 億美元，市盈率為-48.88，β係數為 0.15。公司的流動比率為 3.39，速動比率為 2.65，負債權益比為 0.40。公司的 50 天簡單移動平均線為$8.14，200 天簡單移動平均線為$9.60。</p>
</div><p>Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts' expectations of $71.95 million. During the same period last year, the firm posted $0.02 EPS. Research analysts forecast that Pharming Group will post -0.03 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>藥明康德集團（NASDAQ:PHAR - 獲取免費報告）上次發佈財報是在 8 月 1 日星期四。公司當季每股收益為（$0.01）。藥明康德集團的淨資產收益率為-5.69%，淨利潤率為-4.65%。該季度公司的營收為 7409 萬美元，而分析師預期為 7195 萬美元。去年同期，該公司每股收益為$0.02。研究分析師預測，藥明康德集團今年財年每股盈利將為-0.03 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 32.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company's stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC's holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對藥明康德集團股票的持股。Silverberg Bernstein Capital Management LLC 根據最新提交給證券交易委員會的 13F 文件顯示，該基金在第二季度增持了藥明康德集團（NASDAQ:PHAR - 免費報告）的股份，增幅為 32.3%。該機構投資者在該時期內新增了 5725 股，持有公司股票 23435 股。Silverberg Bernstein Capital Management LLC 持有的藥明康德集團股份價值 196,000 美元。目前有 0.03% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Pharming Group Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>藥明康德集團公司簡介（獲取免費報告）</h2>
</div><p>Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.</p>
<div class="lb-trans"><p>藥明康德集團 N.V.是一家生物製藥公司，致力於開發和銷售用於治療罕見疾病的蛋白替代療法和精準藥物，在美國、歐洲和國際市場銷售。該公司提供 RUCONEST，一種重組 C1 酯酶抑制劑，用於治療成年和青少年急性家族性性水腫（HAE）患者的急性發作；以及 Joenja（leniolisib），一種口服小分子 PI3Kδ抑制劑，用於治療活化磷脂酰肌醇 3-激酶δ綜合徵。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Pharming Group</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li>
<li>How to Start Investing in Real Estate</li>
<li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>3 家健康押息股票值得購買</li>
<li>Target 擊中目標：第二季度盈利超出預期</li>
<li>如何開始投資房地產</li>
<li>特斯拉的反彈剛剛開始？為什麼你應該考慮購買</li>
<li>投資者必須瞭解的場外交易股票</li>
<li>Stanley Druckenmiller 的最新賭注：MELI—你應該跟隨嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Elites' Plot: Control Trump and YOUR Money! (From Golden Crest)(Ad)</p>
<div class="lb-trans"><p>→ 精英們的陰謀：控制特朗普和你的金錢！（來自 Golden Crest）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9184&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pharming Group right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 購買藥明康德集團股票？</h2>
</div><p>Before you consider Pharming Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買藥明康德集團股票之前，您可能需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而藥明康德集團不在名單上。</p>
</div><p>While Pharming Group currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管藥明康德集團目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Pharming Group（納斯達克：PHAR）交易量異常高